UPDATE 1-Allergan, Molecular Partners eye drug meets main goal in two studies
July 19, 2018 at 09:02 AM EDT
Allergan Plc and Molecular Partners AG said on Thursday their treatment for neovascular age-related macular degeneration, a leading cause of vision loss among people over 65, met the main goal in two late-stage studies.
